Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02415374

Enrollment

Registered

2015-04-14

Start date

2015-01-05

Completion date

2015-07-15

Last updated

2021-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Avenanthramides, Bioavailability, Metabolism

Brief summary

The purpose of the study is to examine whether orally ingested oat avenanthramides (AVA) in oat flour cookies are bioavailable in humans by measuring plasma and urine concentrations of AVAs and their potential metabolites after ingestion. The blood and urine concentrations will be quantified at several different time points after the oat flour cookies are consumed to characterize the concentration-time profile.

Interventions

OTHERAvenanthramides

AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Male and female non-obese subjects (18kg/M2\<BMI\<28kg/M2) * Age 20-45 years) * Sign an informed consent form approved by UMN-IRB * Willing to avoid oat consumption and rigorous physical activity the day prior to and through test, and consume a low-flavonoid diet for 1 week prior to the study

Exclusion criteria

* Presence of GI conditions that interfere with absorption; * Clinically significant endocrine, cardiovascular, pulmonary, renal, hepatic, pancreatic, biliary or neurologic disorders; * Major trauma or surgery within 3 months of visit; * Cancer in the prior 2 years; * Allergic to oat products; * Women who are pregnant or lactating; * Smoking; * Drinking alcohol \>5 drinks/week; * Using nutraceuticals; * Blood pressure medication; * NSAID (\>800 mg ibuprofen/week); * Vitamin supplementation; * Anticoagulants or hypoglycemic drugs; * Oat products consumption the day before the test; * Rigorous physical activity the day before the test; * Consumption of a high-flavonoid diet in the week prior to the test.

Design outcomes

Primary

Measure	Time frame
iAUC for each AVA	0-10 hours
Cmax for each AVA	0-10 hours
Tmax for each AVA	0-10 hours
T1/2 for each AVA	0-10 hours

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026